Modulator therapy: rates and stages of respiratory bacteriome restoration in cystic fibrosis patients chronically infected with Pseudomonadota
Open Access
- 22 May 2026
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Abstract
Chronic lung infection caused by Pseudomonadota (PCH) in patients with cystic fibrosis (pwCF) is difficult to eradicate. CFTR modulators have a potential rKeywords
All Related Versions
This publication has 54 references indexed in Scilit:
- Change in pulmonary pathogens 3 years after elexacaftor/tezacaftor/ivacaftor: an observational study in the Danish cystic fibrosis cohortClinical Microbiology and Infection, 2025
- Comparative Efficacy of CFTR Modulators: A Network Meta-analysisLung, 2025
- ECFS best practice guidelines: the 2018 revisionJournal of Cystic Fibrosis, 2018
- Cystic fibrosisThe Lancet, 2016
- Production of extended-spectrum β -lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiotaInternational Journal of Antimicrobial Agents, 2016
- Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trialsJournal of Cystic Fibrosis, 2011
- Species identification of staphylococci by amplification and sequencing of the tuf gene compared to the gap gene and by matrix-assisted laser desorption ionization time-of-flight mass spectrometryEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- Characterizing aggressiveness and predicting future progression of CF lung diseaseJournal of Cystic Fibrosis, 2009
- The Streptococcus milleri group—An unrecognized cause of disease in cystic fibrosis: A case series and literature reviewPediatric Pulmonology, 2008
- Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patientsJournal of Cystic Fibrosis, 2003